Trial reportNutrition journal2026
Efficacy and tolerability of native (undenatured) type II collagen supplementation for joint health in healthy volunteers: a randomized double-blind placebo-controlled study.
Trial report in Nutrition journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05282992 (A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Tolerability of a Food Supplement in Healthy Volunteers With Joint Discomfort), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Tolerability of a Food Supplement in Healthy Volunteers With Joint Discomfort
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn non-osteoarthritic individuals, the appearance of joint discomfort with physical activity is a potential indicator of initial joint degeneration. The present study aimed to evaluate the efficacy and tolerability of native (undenatured) type-II collagen in the joint function of healthy volunteers who experienced joint discomfort as a result of physical activity.
methodsThis prospective, randomized, double-blind, placebo-controlled-study, included seventy-four healthy subjects with joint discomfort during physical activity. Participants were randomized to receive placebo (PBO) or native (undenatured) type-II collagen (CN2) at 40 mg/d for 180 days. Joint function and time to recover from knee discomfort after a standardized exercise protocol were evaluated. CTX-II was analyzed as biomarker of cartilage degradation.
resultsIn both groups a significant improvement in joint function measured with the KOOS score was detected at 180 days, but improvements from baseline were detected earlier in the CN2 as compared to PBO group for KOOS pain, Symptoms and Quality of Life. In the subgroups of subjects with milder basal joint discomfort during activity (VAS≤40 mm) differences between groups in improvement from baseline were detected at 180 days for KOOS pain and Quality of Life subscales. Between-group differences were also detected in time to recover after cycling in the air test. In the subgroups of subjects with higher basal joint discomfort during activity (VAS>40 mm) between-group differences were detected on the progression of CTX-II concentration from baseline, which decreased in CN2 and increased in PBO group.
conclusionsThis study found that supplementation with CN2, containing native (undenatured) type II collagen supports certain aspects of joint health in people who experience joint discomfort after exercise, including improvements in joint function, discomfort and their impact on quality of life.
trial registrationThe study was registered at ClinicalTrials.gov (NCT05282992) on March 16, 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.